Source:http://linkedlifedata.com/resource/pubmed/id/10888226
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2000-10-4
|
pubmed:abstractText |
Integrin alpha 5 beta 1 and alpha 2 beta 1 are the major integrin receptors in human hepatocytes. However, in human hepatocellular carcinoma cells it was found that the expression of integrin alpha 5 beta 1 was decreased and another integrin alpha 6 beta 1 increased. In this study, the SMMC7721 human hepatocellular carcinoma cells cotransfected or singly transfected with integrin alpha 5 and/or beta 1 cDNAs were established, and designated alpha 5 beta 1.6-7721, alpha 5.3-7721, and beta 1.6-7721 cell lines, respectively. Transfection with cDNAs of integrin alpha 5 and beta 1 subunits resulted in the over expression of each integrin and modified biological properties, including a slowed growth rate, changes in the cell cycle from 15.5% of control cells in the G2/M phase to 12.1%, 9.6% and 9.4% in alpha 5.3-7721, beta 1.6-7721, alpha 5 beta 1.6-7721, respectively, and a decrease in the Cell Mitosis Index from 1.6 in controls to 0.96, 0.95, and 0.72, and 34%, 28% and 52% derived from colony forming ability, respectively. Tumorigenicity was also tested in nude mice with inoculation of cells subcutaneously. Tumor masses growing in nude mice following inoculation with beta 1.6-7721, and alpha 5 beta 1.6-7721 cells weighed only 52% or 31% those of control cells. These results indicated that deletion or low expression of integrin alpha 5 beta 1 may play an important role in the development of hepatocellular carcinoma. Therefore, induction of expression of the integrin alpha 5 beta 1 in malignant cells could be a potential means of treating hepatocellular carcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0300-8177
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
207
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
49-55
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10888226-Animals,
pubmed-meshheading:10888226-Carcinogenicity Tests,
pubmed-meshheading:10888226-Carcinoma, Hepatocellular,
pubmed-meshheading:10888226-Cell Cycle,
pubmed-meshheading:10888226-Cell Division,
pubmed-meshheading:10888226-Colony-Forming Units Assay,
pubmed-meshheading:10888226-Flow Cytometry,
pubmed-meshheading:10888226-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:10888226-Humans,
pubmed-meshheading:10888226-Injections, Subcutaneous,
pubmed-meshheading:10888226-Liver Neoplasms,
pubmed-meshheading:10888226-Mice,
pubmed-meshheading:10888226-Mice, Nude,
pubmed-meshheading:10888226-Neoplasm Transplantation,
pubmed-meshheading:10888226-Receptors, Fibronectin,
pubmed-meshheading:10888226-Transfection
|
pubmed:year |
2000
|
pubmed:articleTitle |
Over expression of integrin alpha 5 beta 1 in human hepatocellular carcinoma cell line suppresses cell proliferation in vitro and tumorigenicity in nude mice.
|
pubmed:affiliation |
Key Laboratory of Glycoconjugate Research, Ministry of Health, Department of Biochemistry, Shanghai Medical University, China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|